Multiple Myeloma Clinical Trial

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Summary

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Relapsed or refractory multiple myeloma (MM) and must:

have documented disease progression during or after their last myeloma therapy
be refractory to, intolerant to, or not a candidate for available, established therapies known to provide clinical benefit in MM
Must have measurable disease
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
Agree to follow the CC-92480 Pregnancy Prevention Plan (PPP)

Exclusion Criteria:

Known active or history of central nervous system (CNS) involvement of MM
Plasma cell leukemia; Waldenstrom's macroglobulinemia; polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome; or clinically significant light-chain amyloidosis.
Impaired cardiac function or clinically significant cardiac disease
Previous SARS-CoV-2 infection within 14 days for asymptomatic or mild symptomatic infections or 28 days for severe/critical illness prior to Cycle 1 Day 1 (C1D1)
For Part 1: received prior therapy with CC-92480
For Part 2: received prior therapy with CC-92480, tazemetostat, BMS-986158, or trametinib
Previously received allogeneic stem-cell transplant at any time or received autologous stem-cell transplant within 12 weeks of initiating study treatment

Received any of the following within 14 days prior to initiating study treatment:

Plasmapheresis
Major surgery
Radiation therapy other than local therapy for myeloma associated bone lesions
Use of any systemic anti-myeloma drug therapy
Used any investigational agents within 28 days or 5 half-lives (whichever is shorter) prior to initiating study treatment
COVID-19 vaccine within 14 days prior to C1D1

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

220

Study ID:

NCT05372354

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

Uab Comprehensive Cancer Center
Birmingham Alabama, 35233, United States More Info
Luciano Costa, Site 0002
Contact
205-934-9695
John Theurer Cancer Center at Hackensack UMC
Hackensack New Jersey, 07601, United States More Info
David Siegel, Site 0013
Contact
551-996-8704
Memorial Sloan Kettering Cancer Center
New York New York, 10021, United States More Info
Saad Usmani, Site 0007
Contact
980-442-2000
Local Institution - 0004
Toronto Ontario, M5G 2, Canada More Info
Site 0004
Contact
Local Institution - 0012
Oslo Outside US And Canada, 0450, Norway More Info
Site 0012
Contact
Local Institution - 0005
Madrid , 28041, Spain More Info
Site 0005
Contact
Local Institution - 0003
Santander , 39008, Spain More Info
Site 0003
Contact
Leicester Royal Infirmary
Leicester Leicestershire, LE1 5, United Kingdom More Info
Mamta Garg, Site0001
Contact
+441162586037
Local Institution - 0014
Liverpool Merseyside, L7 8Y, United Kingdom
Local Institution - 0016
Oxford Oxfordshire, OX3 7, United Kingdom More Info
Site 0016
Contact

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

220

Study ID:

NCT05372354

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.